AI-generated analysis. Always verify with the original filing.
USANA Health Sciences, Inc. announced Q4 and FY 2025 financial results with net sales of $226.2 million and $925.3 million, respectively, alongside a Q4 GAAP net loss of $1.8 million due to $7.0 million impairment and $6.5 million cost realignment charges, and provided FY 2026 guidance for net sales of $925 million to $1.0 billion. The filing incorporates Exhibits 99.1 and 99.2 detailing results and outlook.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On February 17, 2026, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing it
Regulation FD Disclosure The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by refe
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated February 17, 2026 (furnis
| Metric | Value | Basis |
|---|---|---|
| Net Sales | $925.30 | |
| Net Earnings | $10.80 | GAAP |
| Diluted EPS | $0.58 | GAAP |
| Adjusted Diluted EPS | $1.93 | Non-GAAP |
| Adjusted EBITDA | $101.30 | Non-GAAP |
Net Sales
925-1000
Net Earnings
20.3-26.6
GAAP
Diluted EPS
1.11-1.45
GAAP
Adjusted Diluted EPS
1.95-2.29
Non-GAAP
Adjusted EBITDA
101.3-109.3
Non-GAAP
Buyback Auth.
34